Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what's new?

about

Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what's new?

Item

http://www.wikidata.org/entity/Q38163027

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Multiple myeloma preparative r ...... s transplantation: what's new?

@en

type

Item

label

Multiple myeloma preparative r ...... s transplantation: what's new?

@en

prefLabel

Multiple myeloma preparative r ...... s transplantation: what's new?

@en

P1476

Multiple myeloma preparative r ...... s transplantation: what's new?

@en

P2093

Joseph P McGuirk

http://www.w3.org/2001/XMLSchema#string

Omar S Aljitawi

http://www.w3.org/2001/XMLSchema#string

P2860

Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study.

Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.

The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.

P304

57-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/CER.11.11

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24237297

http://www.w3.org/2001/XMLSchema#string